Dr. Lior Shaltiel reports

NUREXONE ANNOUNCES BINDING MOU WITH MADE SCIENTIFIC FOR U.S. GMP MANUFACTURING AND COMMERCIAL SUPPLY PARTNERSHIP

Nurexone Biologic Inc.'s wholly owned U.S. subsidiary, Exo-Top Inc., together with the company, has signed a binding memorandum of understanding (MOU) with Made Scientific Inc. to establish an exclusive U.S. good manufacturing practice (GMP) manufacturing and commercial exosome supply partnership to support Nurexone's clinical and commercial activities.

The proposed partnership brings together two companies with a shared vision for building scalable U.S. manufacturing infrastructure to support exosome-based therapeutics and commercial exosome products -- two rapidly growing markets.

Made Scientific is a United States-based cell therapy contract development and manufacturing organization (CDMO), which operates a 60,000-square-foot U.S. Food and Drug Administration (FDA) and European Union (EU) GMP Annex 1-compliant facility in Princeton, N.J.

The parties intend to immediately begin the transfer of Nurexone technology in parallel with negotiation of a definitive partnership agreement, with a target of initiating first GMP exosome batches in H1 (first half) 2027.

"Partnering with highly regarded organizations is essential to building world-class manufacturing around novel therapeutic approaches, including exosome-based therapies," said Dr. Lior Shaltiel, chief executive officer of Nurexone. "This allows us to focus on what we do best and create shareholder value, while working with specialized partners to support execution. Made Scientific is an ideal strategic partner because of its manufacturing capabilities, operational expertise and shared long-term vision. Together, we have an opportunity to establish a U.S. manufacturing and commercialization platform to accelerate Nurexone's therapeutic pipeline, including lead candidate ExoPTEN, while creating a foundation for company revenue, commercial growth and leadership in the emerging exosome market."

Syed T. Husain, chairman and chief executive officer of Made Scientific, commented: "Nurexone has developed a differentiated exosome platform with significant clinical and commercial potential. This collaboration combines Nurexone's innovative bone marrow-derived exosome platform with Made Scientific's manufacturing and regulatory expertise, creating an integrated pathway to bring exosome-based therapies from development through commercial supply."

The proposed collaboration builds on Nurexone's broader manufacturing strategy, including bioprocess optimization with Novasign GmbH announced on July 30, 2026. Together, these initiatives are intended to strengthen the infrastructure supporting both Nurexone's therapeutic pipeline and future commercial exosome activities, positioning the company for long-term, sustainable commercial success.

Under the binding MOU, Made Scientific will serve as Nurexone's exclusive U.S. partner for the manufacturing and aseptic fill-finish of Nurexone's bone marrow-derived exosomes. The MOU contemplates that the definitive agreement, if executed, will feature an initial term of five years, with options for successive five-year renewals. If the parties do not execute a definitive agreement within six months of MOU execution, the MOU and continuing obligations, including exclusivity grants, will automatically terminate, subject to specified surviving obligations.

Update regarding BioXtek Inc. letter of intent

The company also announced that Exo-Top has mutually agreed with Florida-based BioXtek not to proceed with the non-binding letter of intent (LOI) previously announced on April 7, 2026. This decision follows Nurexone's strategic pivot to consolidate its U.S. GMP exosome manufacturing infrastructure under the proposed collaboration with Made Scientific. Nurexone and BioXtek intend to explore potential collaborative business opportunities outside of direct production in the near future.

About Made Scientific Inc.

Made Scientific is a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, N.J., Made Scientific combines the agility of a specialist CDMO with the deep technical expertise to deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corp., a global leader in the pharmaceutical and biotechnology sectors.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt Stock Exchange-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, support the company's road map toward clinical trials in the U.S. and Europe. Commercially, the company intends to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top to anchor its North American activity and growth strategy.

We seek Safe Harbor.